Cytoreductive surgery in ovarian cancer: an integrative review
DOI:
https://doi.org/10.11606/issn.1679-9836.v103i6e-224140Keywords:
Ovarian Neoplasms, Cytoreductive Surgical Procedures, Chemotherapy AdjuvantsAbstract
Ovarian cancer ranks fifth on the list of causes of cancer mortality in women. The most used therapeutic approach for this condition is cytoreductive surgery combined with chemotherapy. This review aims to analyze survival related to cytoreductive surgery in cases of ovarian cancer. This occurred through an integrative review of articles from 2018 to 2022, following the PRISMA criteria, in the PubMed database. In total, 32 articles were found and of these, 18 entered this review. Therefore, cytoreduction followed by platinum/taxane-based chemotherapy is the current standard treatment for ovarian cancer. Survival outcomes are inversely related to initial and residual tumor burden after surgery. It appears that cytoreductive surgery is a viable technique that has been associated with good patient outcomes, including a median survival rate of 53 months.
Downloads
References
Laios A. prediciting complete cytoreduction alexandro laios - Google Search [Internet]. www.google.com. https://www.google.com/search?client=safari&rls=en&q=prediciting+complete+cytoreduction+alexandro+laios&ie=UTF-8&oe=UTF-8
Gorodnova TV, Sokolenko AP, Kuligina E, Berlev IV, Imyanitov EN. Principles of clinical management of ovarian cancer. Chinese Clin Oncol. 2018;7(6):56-6. Doi: https://doi.org/10.21037/cco.2018.10.06
Kurman RJ. Blaustein’s pathology of the female genital tract - Catalog - UW-Madison Libraries [Internet]. Wisc.edu. 2024. https://search.library.wisc.edu/catalog/999947979402121
Bottoni P, Scatena R. The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects. Adv Exp Med Biol. 2015;867:229-44. Doi: https://doi.org/10.1007/978-94-017-7215-0_14
Chudecka-Głaz A, Cymbaluk-Płoska A, Wężowska M, Menkiszak J. Could HE4 level measurements during first-line chemotherapy predict response to treatment among ovarian cancer patients? Ahmad A, editor. PLOS ONE. 2018;13(3):e0194270. Doi: https://doi.org/10.1371/journal.pone.0194270
Ali FT, Soliman RM, Hassan NS, Ibrahim AM, El-Gizawy MM, Mandoh AAY, et al. Sensitivity and specificity of microRNA-204, CA125, and CA19.9 as biomarkers for diagnosis of ovarian cancer. Christie E, editor. PLOS ONE. 2022;17(8):e0272308. Doi: https://doi.org/10.1371/journal.pone.0272308
Cardillo N, Devor EJ, Pedra Nobre S, Newtson A, Leslie K, Bender DP, et al. Integrated Clinical and Genomic Models to Predict Optimal Cytoreduction in High-Grade Serous Ovarian Cancer. Cancers. 2022;14(14):3554. Doi: https://doi.org/10.3390/cancers14143554
May T, Altman A, McGee J, Lu L, Xu W, Lane K, et al. Examining Survival Outcomes of 852 Women With Advanced Ovarian Cancer: A Multi-institutional Cohort Study. International Journal of Gynecological Cancer: Official J Internat Gynecol Cancer Soc. 2018;28(5):925-31. https://pubmed.ncbi.nlm.nih.gov/29621126/
Ding T, Tang D, Xi M. The survival outcome and complication of secondary cytoreductive surgery plus chemotherapy in recurrent ovarian cancer: a systematic review and meta-analysis. J Ovarian Res. 2021;14(1). Doi: https://doi.org/10.1186/s13048-021-00842-9
Jiang C, Li Z. Prediction Models for Complete Resection in Secondary Cytoreductive Surgery of Patients With Recurrent Ovarian Cancer. Front Oncol. 2021;11:674637. Doi: https://doi.org/10.3389/fonc.2021.674637
Gockley A, Melamed A, Cronin A, Bookman MA, Burger RA, Cristae MC, et al. Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer. Am J Obstet Gynecol. 2019;221(6):625.e1-14. Doi: https://doi.org/10.1016/j.ajog.2019.06.009
Goldberg RM, Kim SR, Fazelzad R, Li X, Brown TJ, May T. Secondary cytoreductive surgery for recurrent low-grade serous ovarian carcinoma: A systematic review and meta-analysis. Gynecologic Oncology. 2022;164(1):212-20. Doi: https://doi.org/10.1016/j.ygyno.2021.10.080
Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer. NEJM. 2010;363(10):943-53. Doi: https://doi.org/10.1056/nejmoa0908806
Luna-Abanto J, García Ruiz L, Laura Martinez J, Álvarez Larraondo M, Villoslada Terrones V. Liver Resection as Part of Cytoreductive Surgery for Ovarian Cancer. J Gynecol Surg. 2020;36(2):70-5. Doi: https://doi.org/10.1089/gyn.2019.0074
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Vitória Donadoni Costa, Isabela Rutkowski, Beatriz da Silva Meneses, Maria Eduarda Rodrigues Peixoto, Gabriela Furtado de Oliveira, Rodrigo Pederzoli Salvador Marecos
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
